Shaheenah Dawood, Consultant Medical Oncologist at Mediclinic Middle East, shared a post on LinkedIn:
“Hot off the press!
- Adjuvant Selpercatinib led to a statistically significant and clinically meaningful improvement in efs vs placebo in the treatment of patients with early-stage RET fusion–positive NSCLC
- Primary end point met of the phase 3 LIBRETTO-432 trial.”
Other articles featuring Shaheenah Dawood.
